Today marks a monumental advance in HIV prevention. Congratulations to the many researchers who spent nineteen years to get to today’s approval, backed up by the long-term investment needed to get the drug to market. Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections—if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service.
FDA Approves Twice-Yearly HIV Prevention Drug
read more